(.pdf) dr.ssa Antonella Ferro - Progettoeventi

Recommendations

Info

Trastuzumab has transformed the prognosis of HER2+ breast cancer • Secondo le stime presentate all’ASC0 e SABCS 2008, si prevede che in Europa, nei prossimi 10 anni, saranno circa 28.000 le pazienti che avranno tratto beneficio dalla somministrazione di trastuzumab. • E’ stato calcolato che nei prossimi 25 anni 50.000 donne non svilupperanno recidive grazie all’utilizzo di trastuzumab
Definition of resistance In most tumors a multiplicity of genetic alterations contributes to tumor growth and progression intrinsic resistance acquired resistance
Page 1 and 2: Utilizzo dei farmaci nei diversi co
Page 3 and 4: HER2 positive breast cancer “Targ
Page 5 and 6: Trastuzumab (Herceptin) • Il Tras
Page 7 and 8: Trastuzumab binds to ErbB2 on tumou
Page 9 and 10: Antibody-Dependent Cellular Cytotox
Page 11 and 12: Potenziale meccanismo di trastuzuma
Page 13: Malattia adiuvante
Page 17 and 18: DFS: Sequential (Arm B: AC → T
Page 19 and 20: Malattia Neo- adiuvante
Page 21 and 22: Studio NOAH: Event Free Survival ne
Page 23: Trastuzumab has transformed the pro
Page 27 and 28: Truncated HER2 (p95 HER2 ): clinica
Page 29 and 30: Trastuzumab Capecitabine von Minckw
Page 31 and 32: GBG 26/BIG 03-05: main results Cape
Page 33 and 34: Phase III, randomised, controlled s
Page 35 and 36: Lapatinib • Binds to intracellula
Page 37 and 38: Lapatinib may sensitise HER2 positi
Page 39 and 40: Pertuzumab • Pertuzumab, inibitor
Page 41 and 42: HER2 dimerization is key to signali
Page 43 and 44: Trastuzumab binds to subdomain IV o
Page 45 and 46: Trastuzumab and pertuzumab may have
Page 47 and 48: Receptor-T-DM1 complex is internali

(.pdf) dr.ssa Antonella Ferro - Progettoeventi

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?